Detection of elevated levels of soluble -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies
Open Access
- 21 May 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 132 (4), 1093-1101
- https://doi.org/10.1093/brain/awn349
Abstract
A number of neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies (DLB) and multiple system atrophy are characterized by the formation and intraneuronal accumulation of fibrillar aggregates of α-synuclein (α-syn) protein in affected brain regions. These and other findings suggest that the accumulation of α-syn in the brain plays an important role in the pathogenesis of these diseases. However, more recently it has been reported that early amyloid aggregates or ‘soluble oligomers’ are the pathogenic species that lead to neurodegeneration and neuronal cell death rather than the later ‘mature fibrils’. In this study, we investigated the presence of α-syn oligomers in brain lysates prepared from frozen post-mortem brains of normal, Alzheimer's disease and DLB patients. The brain extracts were subjected to high speed centrifugation, to remove insoluble α-syn aggregates, followed by specific detection of soluble oligomers in the supernatants by employing FILA-1, an antibody that specifically binds to α-syn aggregates, but not to α-syn monomers, or to tau or β-amyloid aggregates. Using this novel enzyme-linked immunosorbent assay (ELISA) method to quantify the amounts of α-syn oligomers in the brain extracts, our data clearly show an increase in the levels of soluble oligomers of α-syn in the DLB brains compared to those with Alzheimer's disease and the controls (P < 0.0001). Our findings provide strong evidence to support the contention that elevated soluble oligomers of α-syn are involved in the pathogenesis of DLB. Furthermore, these findings establish FILA-1 as a very sensitive tool for the detection of oligomeric forms of α-syn in human brain lysates.Keywords
This publication has 46 references indexed in Scilit:
- Inhibitors of α-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson’s disease and related disordersExperimental Brain Research, 2006
- THE BIOCHEMISTRY OF PARKINSON'S DISEASEAnnual Review of Biochemistry, 2005
- α-synuclein locus duplication as a cause of familial Parkinson's diseaseThe Lancet, 2004
- Aggregation and neurotoxicity of α-synuclein and related peptidesBiochemical Society Transactions, 2002
- Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseasesNature, 2002
- Review: Formation and Properties of Amyloid-like Fibrils Derived from α-Synuclein and Related ProteinsJournal of Structural Biology, 2000
- Fibrils Formed in Vitro from α-Synuclein and Two Mutant Forms Linked to Parkinson's Disease are Typical AmyloidBiochemistry, 2000
- Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filamentsFEBS Letters, 1998
- Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's diseaseFEBS Letters, 1998
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991